Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, Mikhailovich V, Filipenko M, Menshikova S, Tjulandin S, Pokataev I. Emelyanova M, et al. Among authors: tjulandin s. Ther Adv Med Oncol. 2022 Mar 15;14:17588359221083050. doi: 10.1177/17588359221083050. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35309086 Free PMC article.
Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.
Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, Kekeyeva TV, Moliaka YK, Gervas PA, Kozhemyako VB, Vodolazhskiy DI, Sergeyeva LA, Fattakhova DU, Iyevleva AG, Mitiushkina NV, Kuligina ESh, Barinov AA, Mommaeva MS, Aleksakhina SN, Tsimafeyeu IV, Tjulandin SA. Imyanitov EN, et al. Among authors: tjulandin sa. Mol Diagn Ther. 2016 Aug;20(4):401-6. doi: 10.1007/s40291-016-0213-4. Mol Diagn Ther. 2016. PMID: 27259329
Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
Pokataev I, Kudaibergenova A, Artemyeva A, Popova A, Rumyantsev A, Podluzhny D, Kudashkin N, Fedyanin M, Tryakin A, Tjulandin S. Pokataev I, et al. Among authors: tjulandin s. J Gastrointest Cancer. 2019 Sep;50(3):478-484. doi: 10.1007/s12029-018-0103-6. J Gastrointest Cancer. 2019. PMID: 29675723
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Iveson T, et al. Among authors: tjulandin s. Lancet Oncol. 2014 Aug;15(9):1007-18. doi: 10.1016/S1470-2045(14)70023-3. Epub 2014 Jun 22. Lancet Oncol. 2014. PMID: 24965569 Clinical Trial.
133 results